Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,591,762

« Back to Dashboard

Patent 5,591,762 protects MICARDIS, MICARDIS HCT, and TWYNSTA, and is included in three NDAs. There have been zero Paragraph IV challenges on Micardis HCT and

Summary for Patent: 5,591,762

Title: Benzimidazoles useful as angiotensin-11 antagonists
Abstract:Disclosed herein are angiotensin-II antagonists of the formula ##STR1## wherein R.sub.1 is, other than hydrogen and, inter alia, halogen, lower alkyl or cycloalkyl; R.sub.2 is, inter alia, optionally substituted benzimidazol-2-yl, 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl, butanesultam-1-yl, imidazol-4-yl, and tetrahydobenzimidazol-2-yl; R.sub.3 is, inter alia, lower alkyl; and, R.sub.4 is an acidic group, such as carboxyl or tetrazolyl. An exemplary compound is: (a) 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)-benzimidazol-1-yl] methyl]-biphenyl-2-carboxylic acid.
Inventor(s): Hauel; Norbert (Schemmerhofen, DE), Narr, deceased; Berthold (late of Biberach, DE), Ries; Uwe (Biberch, DE), van Meel; Jacobus C. A. (Mittelbiberach, DE), Wienen; Wolfgang (Biberach/Rissegg, DE), Entzeroth; Michael (Warthausen, DE)
Assignee: Dr. Karl Thomae GmbH (Biberach an der Riss, DE)
Application Number:08/457,204
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent PDF download available with subscription

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
MICARDIS
telmisartan
TABLET;ORAL020850Apr 4, 2000RXNo5,591,762<disabled>TREATMENT OF HYPERTENSION
Boehringer Ingelheim
MICARDIS
telmisartan
TABLET;ORAL020850Nov 10, 1998RXNo5,591,762<disabled>TREATMENT OF HYPERTENSION
Boehringer Ingelheim
MICARDIS
telmisartan
TABLET;ORAL020850Nov 10, 1998RXYes5,591,762<disabled>YYTREATMENT OF HYPERTENSION
Boehringer Ingelheim
MICARDIS HCT
hydrochlorothiazide; telmisartan
TABLET;ORAL021162Nov 17, 2000RXNo5,591,762<disabled>YYTREATMENT OF HYPERTENSION
Boehringer Ingelheim
MICARDIS HCT
hydrochlorothiazide; telmisartan
TABLET;ORAL021162Apr 19, 2004RXYes5,591,762<disabled>YYTREATMENT OF HYPERTENSION
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,591,762

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany41 03 492.9Feb 06, 1991
Germany41 17 121.7May 25, 1991
Germany41 37 812.1Nov 16, 1991
Germany42 01 554.5Jan 22, 1992
Germany42 12 250.3Apr 11, 1992

International Patent Family for Patent: 5,591,762

Country Document Number Publication Date
South Africa9200816Jul 05, 1993
South Africa9300420Jul 21, 1994
South Africa9300529Jan 23, 1995
South Africa9302521Oct 08, 1994
Yugoslavia9892Mar 04, 1999
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc